title: [A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma].
authors.affiliation: Jiangsu Cancer Hospital. Nanjing 210000, China.
authors.forename: Jianqiu
authors.initials: J
authors.lastname: Wu
authors.forename: Yongping
authors.initials: Y
authors.lastname: Song
authors.forename: Liping
authors.initials: L
authors.lastname: Su
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Yu
authors.initials: Y
authors.lastname: Hu
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Zhang
authors.forename: Yuhuan
authors.initials: Y
authors.lastname: Gao
authors.forename: Zuoxing
authors.initials: Z
authors.lastname: Niu
authors.forename: Ru
authors.initials: R
authors.lastname: Feng
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Jiewen
authors.initials: J
authors.lastname: Peng
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Li
authors.forename: Xuenong
authors.initials: X
authors.lastname: Ouyang
authors.forename: Changping
authors.initials: C
authors.lastname: Wu
authors.forename: Weijing
authors.initials: W
authors.lastname: Zhang
authors.forename: Yun
authors.initials: Y
authors.lastname: Zeng
authors.forename: Zhen
authors.initials: Z
authors.lastname: Xiao
authors.forename: Yingmin
authors.initials: Y
authors.lastname: Liang
authors.forename: Yongzhi
authors.initials: Y
authors.lastname: Zhuang
authors.forename: Jishi
authors.initials: J
authors.lastname: Wang
authors.forename: Zimin
authors.initials: Z
authors.lastname: Sun
authors.forename: Hai
authors.initials: H
authors.lastname: Bai
authors.forename: Tongjian
authors.initials: T
authors.lastname: Cui
authors.affiliation: Jiangsu Cancer Hospital. Nanjing 210000, China.
authors.forename: Jifeng
authors.initials: J
authors.lastname: Feng
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab